Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) has been given an average recommendation of “Hold” by the seven ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has issued a buy recommendation on the […]
Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) was the target of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 8,460,000 shares, a drop of 28.7% from the November 30th total of 11,870,000 shares. Based on an average daily trading volume, of 1,990,000 […]
Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) saw a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 8,460,000 shares, a decline of 28.7% from the November 30th total of 11,870,000 shares. Based on an average daily volume of 1,990,000 shares, the short-interest ratio […]
Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) and Cocrystal Pharma (NASDAQ:COCP – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings. Insider & Institutional Ownership 13.4% of Cocrystal […]
Artal Group S.A. boosted its position in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) by 36.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,029,555 shares of the company’s stock after acquiring an additional 813,767 shares during the quarter. […]